---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019727"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:07:56.210670+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials

## Summary
- Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.
- R&D expenses $39.5M, up $20.2M YoY driven by XEN1101 Phase 3 studies and X-NOVA MDD trial.
- Cash $687.3M as of March 31, 2023; expects to fund operations into 2026.
- XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) recruiting; pediatric expansion to include children ≥12.
- Phase 2 X-NOVA MDD study last patient screening expected June 2023; topline data Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-019727
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/0000950170-23-019727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/xene-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019727
- JSON: https://secwatch.observer/filing/0000950170-23-019727.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019727.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: the Company’s financial results for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/0000950170-23-019727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.